WGS
GeneDx Holdings Corp. trades as WGS and has a market capitalization of $2.10 B, making it the #2102 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $427.54M, up 40.0% from the prior year and net income of -$21.00M. This page tracks GeneDx Holdings Corp. through 748 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years GeneDx Holdings Corp.'s revenue grew from $196.17M to $427.54M, a compound annual growth rate of 13.9%. Net profit margin expanded from -15.1% to -4.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-22 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-15 |
| SCHEDULE 13D/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-11 |
| SCHEDULE 13D/A | - | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-04 |
GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | GeneDx, LLC
GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook | GeneDx, LLC
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing | GeneDx, LLC
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C | GeneDx, LLC
The largest companies sharing GeneDx Holdings Corp.'s SEC industry classification (services-health services).
GeneDx Holdings Corp. (WGS) has a market capitalization of $2.10 B as of 2026-07-09, ranking #2102 among US-listed companies.
GeneDx Holdings Corp. reported revenue of $427.54M for fiscal year 2025, an increase of 40.0% year over year.
In its latest fiscal year GeneDx Holdings Corp. reported a net loss of $21.00M.